Purple Biotech Ltd.
PPBT | TA
Overview
Corporate Details
- ISIN(s):
- IL0007650166
- LEI:
- Country:
- Israel
- Address:
- Oppenheimer 4, 7670104 Rehovot
- Website:
- https://purple-biotech.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Purple Biotech is an Israeli biopharmaceutical company focused on developing innovative cancer therapies and advancing oncology research.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-06 16:10 |
Foreign Filer Report
Purple Biotech Reports Second Quarter 2025 Financial Results
|
English | 275.0 KB | |
| 2025-08-06 16:10 |
Foreign Filer Report
Purple Biotech Reports Second Quarter 2025 Financial Results
|
English | 36.9 KB | |
| 2025-07-23 16:11 |
Foreign Filer Report
6K: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Prog…
|
English | 196.4 KB | |
| 2025-07-23 16:11 |
Foreign Filer Report
6K: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Prog…
|
English | 36.8 KB | |
| 2025-06-23 16:18 |
Foreign Filer Report
6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAP…
|
English | 191.8 KB | |
| 2025-06-23 16:18 |
Foreign Filer Report
6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAP…
|
English | 36.9 KB | |
| 2025-06-17 17:08 |
Foreign Filer Report
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients w…
|
English | 214.2 KB | |
| 2025-06-17 17:08 |
Foreign Filer Report
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients w…
|
English | 36.8 KB | |
| 2025-06-04 16:12 |
Regulatory News Service
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Pla…
|
English | 156.4 KB | |
| 2025-06-04 16:12 |
Registration Form
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Pla…
|
English | 36.6 KB | |
| 2025-05-21 16:22 |
Foreign Filer Report
Purple Biotech Reports First Quarter 2025 Financial Results
|
English | 219.5 KB | |
| 2025-05-21 16:22 |
Foreign Filer Report
Purple Biotech Reports First Quarter 2025 Financial Results
|
English | 36.8 KB | |
| 2025-05-12 16:39 |
Foreign Filer Report
6K: Purple Biotech Appoints Shai Lankry as Chief Financial Officer
|
English | 175.6 KB | |
| 2025-05-12 16:39 |
Foreign Filer Report
6K: Purple Biotech Appoints Shai Lankry as Chief Financial Officer
|
English | 36.6 KB | |
| 2025-05-07 01:45 |
Investor Presentation
6K: Purple Biotech Corporate Presentation May 2025
|
English | 30.7 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS |